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Pharmacomechanical Therapy for Deep-Vein Thrombosis
To the Editor: Regarding the recently published
trial by Vedantham et al. (Dec. 7 issue),1 we wish
to comment on the results that show an apparent
lack of effectiveness of pharmacomechanical
catheter-directed thrombolysis in preventing the
post-thrombotic syndrome in patients with acute
proximal deep-vein thrombosis. Only 58% of
the patients had deep-vein thrombosis involving
the iliac or common femoral veins, whereas 42%
had femoral deep-vein thrombosis, which is associated with a lower risk of the post-thrombotic
syndrome.2 In addition, a high percentage of patients (28%) received a venous stent (vs. 5.7% of
the patients in the CAVENT [Catheter-Directed
Venous Thrombolysis in Acute Iliofemoral Vein
Thrombosis] trial3). We wonder whether stent
occlusion may have contributed to a higher incidence of the post-thrombotic syndrome in the
pharmacomechanical-thrombolysis group than
in the control group. Finally, various nonstandardized methods of pharmacomechanical catheterdirected thrombolysis were used, which makes
interpretation difficult. Despite all these factors,
the incidence of moderate-to-severe post-thrombotic syndrome was substantially lower in the
pharmacomechanical-thrombolysis group than
in the control group, and there were similar rates
of major bleeding events at 24 months in the two
groups. Given these issues, we believe that the
outcomes of this trial are not generalizable.
However, this trial does highlight the need for
further studies with careful selection of patients
and a more standardized approach.
Sarju Ganatra, M.D.
Ajay Sharma, M.D.
Michael S. Levy, M.D.
Lahey Hospital and Medical Center
Burlington, MA
sarju.ganatra@lahey.org
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The authors reply: Patients with femoral deepvein thrombosis were included in our trial because they also are at high risk for the postthrombotic syndrome (which occurred in our
trial in 44% of the patients with femoral deepvein thrombosis vs. 50% of those with iliofemoral deep-vein thrombosis).1 Even in patients with
iliofemoral deep-vein thrombosis, pharmacomechanical thrombolysis did not prevent the postthrombotic syndrome (which occurred in 49% of
the patients with iliofemoral deep-vein thrombosis in the pharmacomechanical-thrombolysis
group and in 51% of those in the control group).
However, pharmacomechanical thrombolysis resulted in a lower rate of moderate-to-severe postthrombotic syndrome and in less severity of the
symptoms and signs of the post-thrombotic syndrome than was observed in the control group.
These benefits appeared to be confined to patients with iliofemoral deep-vein thrombosis.
The thrombolytic methods used in this trial
were standardized and reflected contemporary
practice in the United States.2 All the operators
were credentialed, and there were rigorous requirements for thrombolytic-drug administration
and device use. Per accepted practice, stenting
of residual iliac-vein lesions causing a reduction
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Pleural Disease
To the Editor: With regard to the article by
Feller-Kopman and Light (Feb. 22 issue),1 the distinction between spontaneous pneumothorax that
occurs in apparently healthy persons and pneumothorax caused by preexisting pulmonary disease may seem arbitrary in terms of treatment,
but an important aspect of the management of
this condition is an evaluation for genetic disorders.
A total of 10% of patients with spontaneous
pneumothorax have a family history of pneumothorax.2 Heterozygous mutations in the tumorsuppressor gene FLCN predispose to the Birt–
Hogg–Dubé syndrome, which is the most
common genetic disorder in persons with familial pneumothorax. This syndrome, which is
identified in 10 to 15% of persons with familial
pneumothorax, is associated with renal cancer.3
Spontaneous pneumothorax is also a complication of certain genetic disorders that affect the
integrity of connective tissue, transforming
growth factor β signaling, or both. These disorders include Marfan’s syndrome, the Loeys–
Dietz syndrome, vascular Ehlers–Danlos syndrome, and homocystinuria. Moreover, inhibition
of mechanistic target of rapamycin (mTOR) is a
therapeutic target for pulmonary disease in tuberous sclerosis and lymphangioleiomyomatosis.4
The identification of a genetic disorder that
n engl j med 378;18

predisposes to pneumothorax is valuable in guiding surveillance for life-threatening extrathoracic manifestations and in counseling at-risk
family members. Identification of molecular
mechanisms presents possible therapeutic targets.
Houriya Ayoubieh, M.D.
Eyas Alkhalili, M.D
Johns Hopkins University
Baltimore, MD
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To the Editor: Feller-Kopman and Light did not
mention two possible therapeutic options for refractory hepatic hydrothorax. These options are
placement of a transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation.
The use of a TIPS has been investigated in a
number of uncontrolled studies and several case
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